Biotech companies Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics and Zenas BioPharma are working on novel treatments for multiple sclerosis (MS). Each company is focused on various forms of the disease and aims to enhance therapeutic options, whether through inducing remyelination of axons, targeting B cells, providing neuroprotective benefits or through CAR-T therapies for autoimmune disorders. The global MS drug market is expected to grow to $38.94 billion by 2032.
German authorities want your help finding the hackers behind GandCrab and REvil
Daniil Maksimovich Shchukin and Anatoly Sergeevitsch Kravchuk are believed to have made millions from ransomware as a service schemes
